Precipio (PRPO)
Market Price (5/23/2026): $23.65 | Market Cap: $42.2 MilSector: Health Care | Industry: Life Sciences Tools & Services
Precipio (PRPO)
Market Price (5/23/2026): $23.65Market Cap: $42.2 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Advanced Diagnostics, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.9% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 54x Stock price has recently run up significantly12M Rtn12 month market price return is 144% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.4% Key risksPRPO key risks include [1] its history of operating losses creating significant doubt about its ability to continue as a going concern and [2] challenges in securing adequate reimbursement for its diagnostic products. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Advanced Diagnostics, Show more. |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.9% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 54x |
| Stock price has recently run up significantly12M Rtn12 month market price return is 144% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.4% |
| Key risksPRPO key risks include [1] its history of operating losses creating significant doubt about its ability to continue as a going concern and [2] challenges in securing adequate reimbursement for its diagnostic products. |
Qualitative Assessment
AI Analysis | Feedback
1. Mixed Financial Results and Outlook Prevented Sustained Momentum. Precipio's Q1 2026 earnings, announced on May 14, 2026, showed stable revenue of $6.71 million, marginally higher than Q4 2025 revenue of $6.69 million, but Adjusted EBITDA significantly declined to $(0.16) million from $0.96 million in Q4 2025. While the CEO attributed flat revenue to timing and expressed confidence in growing underlying business fundamentals and product pipeline for the second half of 2026, the immediate financial results presented a mixed picture to investors, leading to a largely sideways stock movement.
2. Analyst Skepticism and Neutral Ratings Limited Upside. Wall Street analysts maintained a cautious stance on Precipio. As of May 8, 2026, the consensus rating from one analyst was "Sell." An AI analyst from TipRanks rated PRPO as "Neutral" on May 6, 2026, acknowledging improving fundamentals like revenue growth and positive cash flow but tempering this with concerns about financial-statement quality, consistency, and profitability durability. This lack of strong positive analyst sentiment likely curbed significant upward price movement.
Show more
Stock Movement Drivers
Fundamental Drivers
The -3.0% change in PRPO stock from 1/31/2026 to 5/22/2026 was primarily driven by a -8.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312026 | 5222026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.54 | 23.80 | -3.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 23 | 26 | 13.3% |
| P/S Multiple | 1.8 | 1.6 | -6.8% |
| Shares Outstanding (Mil) | 2 | 2 | -8.2% |
| Cumulative Contribution | -3.0% |
Market Drivers
1/31/2026 to 5/22/2026| Return | Correlation | |
|---|---|---|
| PRPO | -3.0% | |
| Market (SPY) | 8.1% | 16.5% |
| Sector (XLV) | -2.7% | 4.7% |
Fundamental Drivers
The 16.1% change in PRPO stock from 10/31/2025 to 5/22/2026 was primarily driven by a 21.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 5222026 | Change |
|---|---|---|---|
| Stock Price ($) | 20.50 | 23.80 | 16.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 21 | 26 | 21.6% |
| P/S Multiple | 1.5 | 1.6 | 12.4% |
| Shares Outstanding (Mil) | 2 | 2 | -15.1% |
| Cumulative Contribution | 16.1% |
Market Drivers
10/31/2025 to 5/22/2026| Return | Correlation | |
|---|---|---|
| PRPO | 16.1% | |
| Market (SPY) | 9.9% | 8.7% |
| Sector (XLV) | 4.8% | -2.2% |
Fundamental Drivers
The 291.2% change in PRPO stock from 4/30/2025 to 5/22/2026 was primarily driven by a 235.4% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5222026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.08 | 23.80 | 291.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 19 | 26 | 39.4% |
| P/S Multiple | 0.5 | 1.6 | 235.4% |
| Shares Outstanding (Mil) | 1 | 2 | -16.3% |
| Cumulative Contribution | 291.2% |
Market Drivers
4/30/2025 to 5/22/2026| Return | Correlation | |
|---|---|---|
| PRPO | 291.2% | |
| Market (SPY) | 36.0% | 4.9% |
| Sector (XLV) | 8.6% | 2.2% |
Fundamental Drivers
The 95.1% change in PRPO stock from 4/30/2023 to 5/22/2026 was primarily driven by a 174.4% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5222026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.20 | 23.80 | 95.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 26 | 174.4% |
| P/S Multiple | 1.5 | 1.6 | 11.1% |
| Shares Outstanding (Mil) | 1 | 2 | -36.0% |
| Cumulative Contribution | 95.1% |
Market Drivers
4/30/2023 to 5/22/2026| Return | Correlation | |
|---|---|---|
| PRPO | 95.1% | |
| Market (SPY) | 86.3% | 4.9% |
| Sector (XLV) | 18.0% | 4.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PRPO Return | -24% | -65% | -41% | -15% | 315% | 7% | -41% |
| Peers Return | 16% | -55% | 18% | -9% | 39% | -20% | -37% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| PRPO Win Rate | 33% | 33% | 17% | 42% | 75% | 60% | |
| Peers Win Rate | 43% | 32% | 47% | 43% | 50% | 36% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| PRPO Max Drawdown | -70% | -71% | -73% | -36% | -56% | -26% | |
| Peers Max Drawdown | -43% | -60% | -40% | -36% | -44% | -44% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: NEO, FLGT, MYGN, GH, QGEN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/22/2026 (YTD)
How Low Can It Go
| Event | PRPO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -45.9% | -18.8% |
| % Gain to Breakeven | 84.8% | 23.1% |
| Time to Breakeven | 42 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -18.7% | -9.5% |
| % Gain to Breakeven | 22.9% | 10.5% |
| Time to Breakeven | 14 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -59.9% | -6.7% |
| % Gain to Breakeven | 149.3% | 7.1% |
| Time to Breakeven | 800 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -65.9% | -33.7% |
| % Gain to Breakeven | 193.1% | 50.9% |
| Time to Breakeven | 114 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -62.0% | -19.2% |
| % Gain to Breakeven | 163.4% | 23.8% |
| Time to Breakeven | 109 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -92.6% | -3.7% |
| % Gain to Breakeven | 1243.3% | 3.9% |
| Time to Breakeven | 17 days | 6 days |
In The Past
Precipio's stock fell -45.9% during the 2025 US Tariff Shock. Such a loss loss requires a 84.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PRPO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -45.9% | -18.8% |
| % Gain to Breakeven | 84.8% | 23.1% |
| Time to Breakeven | 42 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -59.9% | -6.7% |
| % Gain to Breakeven | 149.3% | 7.1% |
| Time to Breakeven | 800 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -65.9% | -33.7% |
| % Gain to Breakeven | 193.1% | 50.9% |
| Time to Breakeven | 114 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -62.0% | -19.2% |
| % Gain to Breakeven | 163.4% | 23.8% |
| Time to Breakeven | 109 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -92.6% | -3.7% |
| % Gain to Breakeven | 1243.3% | 3.9% |
| Time to Breakeven | 17 days | 6 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -33.8% | -15.4% |
| % Gain to Breakeven | 51.2% | 18.2% |
| Time to Breakeven | 125 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -60.4% | -53.4% |
| % Gain to Breakeven | 152.4% | 114.4% |
| Time to Breakeven | 58 days | 1085 days |
In The Past
Precipio's stock fell -45.9% during the 2025 US Tariff Shock. Such a loss loss requires a 84.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Precipio (PRPO)
AI Analysis | Feedback
1. Precipio is like a specialized Quest Diagnostics or LabCorp, focusing on advanced diagnostic testing for blood cancers.
2. Precipio is like Exact Sciences, but dedicated to blood cancer diagnostics, offering both testing services and proprietary technologies.
3. Precipio is like a niche Illumina or Thermo Fisher Scientific, developing specialized molecular diagnostic technologies and reagents for blood cancer.
AI Analysis | Feedback
- Diagnostic blood cancer testing services: Precipio provides specialized services for diagnosing blood cancers.
- IV-Cell: A proprietary cell culture media designed for the simultaneous culturing of four hematopoietic cell lineages.
- HemeScreen: A suite of robust genetic diagnostic panels used for advanced testing.
- ICE-COLD PCR: A proprietary and patented specimen technology that enhances the sensitivity of molecular-based tests, also sold as kits to bio-pharma customers.
- COVID-19 antibody tests: Tests offered to detect antibodies for the COVID-19 virus.
AI Analysis | Feedback
Precipio (PRPO) primarily sells its diagnostic products, reagents, and services to other companies and institutions, rather than directly to individuals. Based on the provided description, its major customers fall into the following categories:
- Bio-pharma companies: Precipio sells its ICE-COLD-PCR technology kits to customers within the bio-pharmaceutical industry.
- Academic institutions: The company has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, indicating these institutions are recipients of its technologies and services.
- Healthcare providers and diagnostic laboratories: Precipio provides diagnostic blood cancer testing services, IV-Cell (cell culture media), HemeScreen (genetic diagnostic panels), and COVID-19 antibody tests. These types of products and services are typically utilized by hospitals, clinics, and reference laboratories for patient diagnosis and research.
AI Analysis | Feedback
null
AI Analysis | Feedback
Ilan Danieli, CEO Ilan Danieli has served as Precipio's CEO since co-founding the company in early 2011. He brings over 20 years of experience managing small and medium-sized companies. His previous experiences include serving as COO of Osiris, a publicly-traded company, and working at Laurus Capital Management, a multi-billion dollar hedge fund. Danieli was also Co-Owner and Director of Marketing for Link Productions and Magnolia Broadband. Matthew Gage, CFO Matthew Gage was appointed Chief Financial Officer of Precipio in March 2022. He previously served as the Director of Financial Reporting and Analysis for Precipio, a role he took on in June 2017 after the company's acquisition of Transgenomic Inc. He had held the same position at Transgenomic Inc. since 2014. Gage has over 30 years of experience in corporate finance, working with both private and public companies. A. Zaki Sabet, COO A. Zaki Sabet has been with Precipio since co-founding the company in 2011 and currently serves as its Chief Operating Officer. He possesses over 12 years of experience in laboratory management, with a primary focus on cancer diagnostics. Before joining Precipio, Zaki served as a consultant with the College of American Pathologists (CAP) and various diagnostic companies, helping them establish specialized cancer testing operations. Ayman Mohamed, MD, CTO Dr. Ayman Mohamed is one of the co-founders of Precipio and currently holds the position of Chief Technology Officer. He is responsible for the entire process of proprietary technology development, from conceptualization and invention to technical implementation in Precipio's clinical laboratories. Prior to Precipio, Dr. Mohamed held technical and research roles at commercial diagnostic companies and academic centers such as Yale University. Miri Chiko-Radomski, Chief Legal Counsel and People Officer Miri Chiko-Radomski brings extensive international legal experience from Sweden, England, and Israel to her role as Chief Legal Counsel and People Officer at Precipio. She specializes in advising on equity capital markets, general corporate matters, corporate restructurings, corporate governance, and M&A transactions.AI Analysis | Feedback
-
Challenges in Achieving Sustained Profitability and Financial Stability: Precipio has historically faced recurring operating losses, leading to "going concern" disclosures in financial audits. While the company has made strides in improving its financial health, including debt reduction and enhanced cash flow from operations, it has not yet achieved consistent GAAP net profitability and reported a net loss in Q3 2025. The company's Altman Z-Score, which assesses the likelihood of financial distress, places it in the "distress zone". Furthermore, Precipio's relatively small market capitalization contributes to high stock volatility and liquidity risks.
-
Regulatory and Technological Risks in the Diagnostics Industry: Operating in the highly regulated healthcare sector, Precipio is exposed to significant regulatory and technological risks. Evolving regulations, such as potential FDA rulings on Laboratory Developed Tests (LDTs), could necessitate costly product submission for approval. The development and commercialization of diagnostic products also involve inherent product liability risks, including claims arising from inaccurate test results that could lead to adverse health outcomes for patients. Additionally, like all healthcare companies handling sensitive data, Precipio faces cybersecurity and data privacy concerns, as evidenced by a 2024 incident involving its clearinghouse service, Change Healthcare, which impacted cash inflows, although the advance received has since been repaid.
-
Intense Competition and Limited Market Penetration: Precipio operates in a highly competitive cancer diagnostics market with numerous established and emerging players. The company's estimated market share remains under 1% of its total addressable market. This competitive landscape requires continuous innovation and effective market strategies to differentiate its proprietary technologies and services, such as IV-Cell, HemeScreen, and ICE-COLD PCR, and to gain wider adoption against a diverse range of competitors.
AI Analysis | Feedback
The rapid development and increasing commercialization of multi-cancer early detection (MCED) tests and advanced liquid biopsy platforms pose an emerging threat. These technologies aim to detect multiple types of cancer, often including blood cancers, from a single blood sample with high sensitivity and specificity, potentially much earlier than current methods. If these comprehensive, non-invasive tests gain widespread adoption for screening and early diagnosis, they could significantly disrupt the market for Precipio's more targeted diagnostic blood cancer testing services and genetic panels (HemeScreen) by offering a broader, potentially earlier, and less invasive diagnostic approach from competing large diagnostic and pharma companies.
AI Analysis | Feedback
Precipio, Inc. (NASDAQ: PRPO) operates in several key diagnostic markets. The addressable market sizes for its main products and services are outlined below:
- Diagnostic Blood Cancer Testing Services: The global blood cancer diagnostics market was estimated at approximately USD 10.83 billion in 2024 and is projected to grow to about USD 16.04 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 6.87% from 2025 to 2030. In the United States alone, this market was valued at USD 4.56 billion in 2024 and is predicted to reach around USD 9.04 billion by 2034, with a CAGR of 7.08% from 2025 to 2034. North America held the largest share of the global blood cancer diagnostics market, accounting for 37.7% in 2024.
- IV-Cell (Cell Culture Media): The global cell culture media market, which includes products like IV-Cell, was valued at USD 7.69 billion in 2025 and is expected to reach approximately USD 20.32 billion by 2034, expanding at a CAGR of 11.45% during the forecast period from 2025 to 2034. North America holds the largest revenue share in the cell culture media market, accounting for 38.21% in 2024.
- HemeScreen (Genetic Diagnostic Panels): The global gene panel market, encompassing genetic diagnostic panels such as HemeScreen, was valued at USD 4.85 billion in 2024. It is anticipated to grow to approximately USD 25.17 billion by 2034, exhibiting a CAGR of 17.9% from 2025 to 2034. North America dominated the global gene panel market with a 37% share in 2024, with the U.S. accounting for 72% of the North American market.
- ICE-COLD PCR (Molecular Diagnostics/PCR Technologies): ICE-COLD PCR is a proprietary specimen technology that increases the sensitivity of molecular-based tests. The broader global PCR technologies market was approximately USD 16.90 billion in 2025 and is projected to reach about USD 31.39 billion by 2034, with a CAGR of 7.12% from 2025 to 2034. North America led this market with a 44% share in 2024. The U.S. molecular diagnostics market, which includes PCR technologies, was valued at USD 8.93 billion in 2026 and is projected to reach USD 14.32 billion by 2031.
- COVID-19 Antibody Tests: Precipio launched a COVID-19 rapid antibody test in May 2021. The global COVID-19 antibody detection kit market is projected to reach USD 5.67 billion by 2025, with an anticipated CAGR of 6.9%. North America and Europe together account for approximately USD 10 billion of the global antibody detection kit market. The U.S. COVID-19 detection point-of-care (POC) kits market generated USD 975.2 million in 2022 and is expected to reach USD 769.2 million by 2030, with a negative CAGR of -2.9% from 2023 to 2030.
AI Analysis | Feedback
Precipio, Inc. (PRPO) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:
- Continued Growth in Pathology Services Division: Precipio has demonstrated consistent revenue growth in its Pathology Services Division, with a significant increase in test volume and the adoption of its services by new physicians. For example, in Q3 2025, the Pathology Services Division's revenue increased by 20% quarter-over-quarter, reaching $6 million. Similarly, Q1 2025 saw a 54% year-over-year revenue growth and a 46% increase in test volume for this division, accompanied by 11 new ordering physicians utilizing their services. The company expects pathology division margins to stabilize in the mid-40% range with continued volume increases, further contributing to profitability that can be reinvested into growth.
- Expansion of the Product Division through New Offerings and Customer Acquisition: The Product Division is a significant growth area, driven by the launch of new diagnostic panels and the onboarding of new customers. In Q1 2025, Precipio successfully introduced two new panels and acquired a new customer, with expectations for increased orders. Additionally, two existing customers commenced validations for four new panels. The Product Division's revenue grew by 16% quarter-over-quarter in Q3 2025.
- Expanded Reimbursement and Favorable Regulatory Environment: Key regulatory and reimbursement developments are poised to positively impact revenue. The MolDx approval for Next-Generation Sequencing (NGS) testing is anticipated to boost future Medicare revenue. Furthermore, the reversal of the FDA ruling on Laboratory Developed Tests (LDTs) has removed a prior barrier for some laboratories, which is expected to increase future engagement and adoption of Precipio's products and services.
- Increased Market Penetration and Customer Acquisition: Precipio is focused on broadening its customer base through enhanced distributor relationships and expanded technical support capabilities. Management anticipates that several additional customers will come online in the upcoming quarters, contributing to sustained double-digit growth across both its Pathology Services and Product divisions.
- Operational Efficiencies and Margin Expansion: While not a direct revenue driver, the company's focus on improving operational efficiencies and expanding gross margins is critical for sustainable growth. Precipio's overall gross margins improved to 44% in Q3 2025 from 43% in Q2 2025 and are expected to exceed 50% by mid-2026. This improved profitability allows for greater reinvestment in growth initiatives and strengthens the company's financial position, indirectly fueling future revenue generation.
AI Analysis | Feedback
nullLatest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Precipio Earnings Notes | 12/16/2025 | |
| Precipio Stock Lost 5.1%, Buy Or Wait? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to PRPO.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 20.45 |
| Mkt Cap | 0.9 |
| Rev LTM | 787 |
| Op Inc LTM | -71 |
| FCF LTM | -14 |
| FCF 3Y Avg | -34 |
| CFO LTM | 2 |
| CFO 3Y Avg | -7 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.2% |
| Rev Chg 3Y Avg | 9.1% |
| Rev Chg Q | 6.7% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Inc Chg LTM | 17.8% |
| Op Inc Chg 3Y Avg | 19.6% |
| Op Mgn LTM | -9.1% |
| Op Mgn 3Y Avg | -17.1% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 1.6% |
| CFO/Rev 3Y Avg | -3.1% |
| FCF/Rev LTM | -1.7% |
| FCF/Rev 3Y Avg | -6.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.9 |
| P/S | 1.6 |
| P/Op Inc | -10.4 |
| P/EBIT | -9.1 |
| P/E | -9.6 |
| P/CFO | 32.5 |
| Total Yield | -5.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -6.2% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.5% |
| 3M Rtn | -8.8% |
| 6M Rtn | -22.3% |
| 12M Rtn | 12.0% |
| 3Y Rtn | -34.7% |
| 1M Excs Rtn | -5.5% |
| 3M Excs Rtn | -19.4% |
| 6M Excs Rtn | -28.1% |
| 12M Excs Rtn | -18.6% |
| 3Y Excs Rtn | -114.1% |
Price Behavior
| Market Price | $23.80 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 07/18/2000 | |
| Distance from 52W High | -26.5% | |
| 50 Days | 200 Days | |
| DMA Price | $27.39 | $22.77 |
| DMA Trend | up | up |
| Distance from DMA | -13.1% | 4.5% |
| 3M | 1YR | |
| Volatility | 68.0% | 74.8% |
| Downside Capture | 218.61 | 76.07 |
| Upside Capture | 130.85 | 158.53 |
| Correlation (SPY) | 17.2% | 5.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.79 | 0.89 | 0.79 | 0.43 | 0.28 | 0.24 |
| Up Beta | -1.28 | -1.54 | -1.48 | -1.33 | -0.94 | 0.54 |
| Down Beta | 7.37 | -0.80 | 0.26 | -0.53 | -0.16 | 0.00 |
| Up Capture | 305% | 327% | 254% | 225% | 318% | 11% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 23 | 33 | 60 | 123 | 347 |
| Down Capture | 857% | 178% | 141% | 101% | 2% | 4% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 20 | 31 | 64 | 125 | 380 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRPO | |
|---|---|---|---|---|
| PRPO | 100.3% | 71.1% | 1.27 | - |
| Sector ETF (XLV) | 16.0% | 14.5% | 0.80 | 6.6% |
| Equity (SPY) | 29.5% | 12.0% | 1.86 | 7.2% |
| Gold (GLD) | 35.5% | 26.8% | 1.11 | 4.9% |
| Commodities (DBC) | 42.9% | 18.7% | 1.77 | 6.7% |
| Real Estate (VNQ) | 15.2% | 13.1% | 0.82 | -1.6% |
| Bitcoin (BTCUSD) | -29.5% | 41.7% | -0.73 | 19.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRPO | |
|---|---|---|---|---|
| PRPO | -20.1% | 76.2% | 0.03 | - |
| Sector ETF (XLV) | 5.7% | 14.7% | 0.21 | 8.5% |
| Equity (SPY) | 14.0% | 17.0% | 0.64 | 14.4% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | -1.7% |
| Commodities (DBC) | 10.4% | 19.4% | 0.42 | 6.1% |
| Real Estate (VNQ) | 3.8% | 18.8% | 0.10 | 10.8% |
| Bitcoin (BTCUSD) | 12.2% | 55.3% | 0.42 | 11.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRPO | |
|---|---|---|---|---|
| PRPO | -40.6% | 450.3% | 0.40 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 1.7% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 2.7% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | -1.2% |
| Commodities (DBC) | 7.8% | 17.9% | 0.35 | 4.8% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 2.0% |
| Bitcoin (BTCUSD) | 67.2% | 66.9% | 1.06 | 0.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/27/2026 | 2.5% | 10.2% | -0.8% |
| 5/15/2025 | 10.2% | 36.4% | 52.2% |
| 2/28/2022 | -2.6% | -2.6% | -11.8% |
| 7/28/2021 | 0.7% | -2.0% | 19.8% |
| 7/22/2020 | -11.6% | -16.3% | 85.0% |
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 3 |
| # Negative | 2 | 3 | 2 |
| Median Positive | 2.5% | 23.3% | 52.2% |
| Median Negative | -7.1% | -2.6% | -6.3% |
| Max Positive | 10.2% | 36.4% | 85.0% |
| Max Negative | -11.6% | -16.3% | -11.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Sell | 5212026 | 25.00 | 500 | 12,500 | 97,500 | Form | |
| 2 | Sandberg, Richard A | Direct | Sell | 5212026 | 24.89 | 2,034 | 50,632 | 202,677 | Form | |
| 3 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Sell | 5212026 | 24.42 | 600 | 14,652 | 107,451 | Form | |
| 4 | Sabet, Ahmed Zaki | Chief Operating Officer | Direct | Buy | 4102026 | 27.93 | 19 | 531 | 28,880 | Form |
| 5 | Sabet, Ahmed Zaki | Chief Operating Officer | Direct | Buy | 1062026 | 23.40 | 20 | 468 | 17,199 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.